;PMID: 10877072
;source_file_2859.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..101] = [t:48..101]
;2)sentence:[e:102..140] = [t:102..140]
;3)section:[e:144..179] = [t:144..179]
;4)section:[e:183..248] = [t:183..248]
;5)sentence:[e:252..317] = [t:252..317]
;6)sentence:[e:318..417] = [t:318..417]
;7)sentence:[e:418..534] = [t:418..534]
;8)sentence:[e:535..632] = [t:535..632]
;9)sentence:[e:633..774] = [t:633..774]
;10)sentence:[e:775..874] = [t:775..874]
;11)sentence:[e:876..982] = [t:876..982]
;12)sentence:[e:983..1096] = [t:983..1096]
;13)sentence:[e:1097..1221] = [t:1097..1221]
;14)sentence:[e:1222..1319] = [t:1222..1319]
;15)section:[e:1323..1368] = [t:1323..1368]

;section 0 Span:0..42
;Eur J Pediatr Surg.  2000 Apr;10(2):79-82.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..13] Pediatr)
        (NNP:[14..18] Surg) (.:[18..19] .) (CD:[21..25] 2000)
        (CC:[26..33] Apr;10-LRB-) (CD:[33..34] 2) (-RRB-:[34..35] -RRB-)
        (::[35..36] :) (CD:[36..38] 79) (::[38..39] -) (CD:[39..41] 82)
        (.:[41..42] .)))

;sentence 1 Span:48..101
;Neuroblastoma: induction of differentiation (Part I).
;[48..61]:malignancy-type:"Neuroblastoma"
(SENT
  (NP-HLN
    (NP (NN:[48..61] Neuroblastoma))
    (::[61..62] :)
    (NP
      (NP (NN:[63..72] induction))
      (PP (IN:[73..75] of)
        (NP (NN:[76..91] differentiation))))
    (PRN (-LRB-:[92..93] -LRB-)
      (NP (NN:[93..97] Part) (CD:[98..99] I))
      (-RRB-:[99..100] -RRB-))
    (.:[100..101] .)))

;sentence 2 Span:102..140
;Basical science in  pediatric surgery.
(SENT
  (NP-HLN
    (NP (JJ:[102..109] Basical) (NN:[110..117] science))
    (PP (IN:[118..120] in)
      (NP (JJ:[122..131] pediatric) (NN:[132..139] surgery)))
    (.:[139..140] .)))

;section 3 Span:144..179
;Girgert R, Schweizer P, Schwable J.
(SEC
  (FRAG (NNP:[144..151] Girgert) (NNP:[152..153] R) (,:[153..154] ,)
        (NNP:[155..164] Schweizer) (NNP:[165..167] P,) (NNP:[168..176] Schwable)
        (NNP:[177..179] J.)))

;section 4 Span:183..248
;Department of Pediatric Surgery, University of Tubingen, Germany.
(SEC
  (FRAG (NNP:[183..193] Department) (IN:[194..196] of)
        (NNP:[197..206] Pediatric) (NNP:[207..214] Surgery) (,:[214..215] ,)
        (NNP:[216..226] University) (IN:[227..229] of) (NNP:[230..238] Tubingen)
        (,:[238..239] ,) (NNP:[240..247] Germany) (.:[247..248] .)))

;sentence 5 Span:252..317
;Neuroblastoma is the second-most common solid tumor in childhood.
;[252..265]:malignancy-type:"Neuroblastoma"
;[292..303]:malignancy-type:"solid tumor"
;[307..316]:malignancy-developmental-state:"childhood"
(SENT
  (S
    (NP-SBJ (NN:[252..265] Neuroblastoma))
    (VP (VBZ:[266..268] is)
      (NP-PRD (DT:[269..272] the)
        (ADJP
          (ADVP (JJ:[273..279] second) (HYPH:[279..280] -) (RBS:[280..284] most))
          (JJ:[285..291] common))
         (JJ:[292..297] solid) (NN:[298..303] tumor))
      (PP (IN:[304..306] in)
        (NP (NN:[307..316] childhood))))
    (.:[316..317] .)))

;sentence 6 Span:318..417
;The majority  of patients have a very poor outcome due to aggressive growth
;and metastatic  spread.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[318..321] The) (NN:[322..330] majority))
      (PP (IN:[332..334] of)
        (NP (NNS:[335..343] patients))))
    (VP (VBP:[344..348] have)
      (NP (DT:[349..350] a)
        (ADJP (RB:[351..355] very) (JJ:[356..360] poor))
        (NN:[361..368] outcome))
      (PP (IN:[369..372] due)
        (PP (TO:[373..375] to)
          (NP
            (NP (JJ:[376..386] aggressive) (NN:[387..393] growth))
            (CC:[394..397] and)
            (NP (JJ:[398..408] metastatic) (NN:[410..416] spread))))))
    (.:[416..417] .)))

;sentence 7 Span:418..534
;In contrast, in rare cases, spontaneous regression or differentiation 
;towards a benign ganglioneuroma are observed.
;[499..505]:malignancy-clinical-stage:"benign"
;[506..520]:malignancy-type:"ganglioneuroma"
(SENT
  (S
    (PP (IN:[418..420] In)
      (NP (NN:[421..429] contrast)))
    (,:[429..430] ,)
    (PP (IN:[431..433] in)
      (NP (JJ:[434..438] rare) (NNS:[439..444] cases)))
    (,:[444..445] ,)
    (NP-SBJ-2
      (NP
        (NP
          (NML-1 (JJ:[446..457] spontaneous))
          (NN:[458..468] regression))
        (CC:[469..471] or)
        (NP
          (NML-1 (-NONE-:[471..471] *P*))
          (NN:[472..487] differentiation)))
      (PP (IN:[489..496] towards)
        (NP (DT:[497..498] a) (JJ:[499..505] benign)
            (NN:[506..520] ganglioneuroma))))
    (VP (VBP:[521..524] are)
      (VP (VBN:[525..533] observed)
        (NP-2 (-NONE-:[533..533] *))))
    (.:[533..534] .)))

;sentence 8 Span:535..632
;The mechanism leading to  differentiation of neuroblastoma is of particular
;therapeutic interest.
;[580..593]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[535..538] The) (NN:[539..548] mechanism))
      (VP (VBG:[549..556] leading)
        (PP-CLR (TO:[557..559] to)
          (NP
            (NP (NN:[561..576] differentiation))
            (PP (IN:[577..579] of)
              (NP (NN:[580..593] neuroblastoma)))))))
    (VP (VBZ:[594..596] is)
      (PP-PRD (IN:[597..599] of)
        (NP (JJ:[600..610] particular) (JJ:[611..622] therapeutic)
            (NN:[623..631] interest))))
    (.:[631..632] .)))

;sentence 9 Span:633..774
;In this  paper we report the results of our attempts to induce the expression
;of genes  necessary for differentiation of neuroblastoma cells.
;[754..767]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[633..635] In)
      (NP (DT:[636..640] this) (NN:[642..647] paper)))
    (NP-SBJ (PRP:[648..650] we))
    (VP (VBP:[651..657] report)
      (NP
        (NP (DT:[658..661] the) (NNS:[662..669] results))
        (PP (IN:[670..672] of)
          (NP (PRP$:[673..676] our) (NNS:[677..685] attempts)
            (S
              (NP-SBJ (-NONE-:[685..685] *))
              (VP (TO:[686..688] to)
                (VP (VB:[689..695] induce)
                  (NP
                    (NP (DT:[696..699] the) (NN:[700..710] expression))
                    (PP (IN:[711..713] of)
                      (NP
                        (NP (NNS:[714..719] genes))
                        (ADJP (JJ:[721..730] necessary)
                          (PP (IN:[731..734] for)
                            (NP
                              (NP (NN:[735..750] differentiation))
                              (PP (IN:[751..753] of)
                                (NP (NN:[754..767] neuroblastoma)
                                    (NNS:[768..773] cells))))))))))))))))
    (.:[773..774] .)))

;sentence 10 Span:775..874
;TrkA codes for the high  affinity receptor of NGF, a neurotrophin known to
;promote differentiation.
;[775..779]:gene-rna:"TrkA"
;[809..824]:gene-protein:"receptor of NGF"
;[828..840]:gene-protein:"neurotrophin"
(SENT
  (S
    (NP-SBJ (NN:[775..779] TrkA))
    (VP (VBZ:[780..785] codes)
      (PP-CLR (IN:[786..789] for)
        (NP
          (NP
            (NP (DT:[790..793] the)
              (NML (JJ:[794..798] high) (NN:[800..808] affinity))
              (NN:[809..817] receptor))
            (PP (IN:[818..820] of)
              (NP (NN:[821..824] NGF))))
          (,:[824..825] ,)
          (NP
            (NP (DT:[826..827] a) (NN:[828..840] neurotrophin))
            (VP (VBN:[841..846] known)
              (S
                (NP-SBJ (-NONE-:[846..846] *))
                (VP (TO:[847..849] to)
                  (VP (VB:[850..857] promote)
                    (NP (NN:[858..873] differentiation))))))))))
    (.:[873..874] .)))

;sentence 11 Span:876..982
;Treatment with retinoic acid caused a 3-fold increase of the trkA expression
;in  neuroblastoma cell lines.
;[937..941]:gene-generic:"trkA"
;[957..970]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[876..885] Treatment))
      (PP (IN:[886..890] with)
        (NP (JJ:[891..899] retinoic) (NN:[900..904] acid))))
    (VP (VBD:[905..911] caused)
      (NP
        (NP (DT:[912..913] a)
          (QP (CD:[914..915] 3) (HYPH:[915..916] -) (JJ:[916..920] fold))
          (NN:[921..929] increase))
        (PP (IN:[930..932] of)
          (NP (DT:[933..936] the) (NN:[937..941] trkA)
              (NN:[942..952] expression))))
      (PP-LOC (IN:[953..955] in)
        (NP (NN:[957..970] neuroblastoma) (NN:[971..975] cell)
            (NNS:[976..981] lines))))
    (.:[981..982] .)))

;sentence 12 Span:983..1096
;Neurofibromin, the gene product of the NF-1 gene, is  involved in
;downregulation of the activity of ras-proteins.
;[983..996]:gene-protein:"Neurofibromin"
;[1022..1026]:gene-rna:"NF-1"
;[1083..1086]:gene-protein:"ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[983..996] Neurofibromin))
      (,:[996..997] ,)
      (NP
        (NP (DT:[998..1001] the) (NN:[1002..1006] gene)
            (NN:[1007..1014] product))
        (PP (IN:[1015..1017] of)
          (NP (DT:[1018..1021] the) (NN:[1022..1026] NF-1)
              (NN:[1027..1031] gene)))))
    (,:[1031..1032] ,)
    (VP (VBZ:[1033..1035] is)
      (VP (VBN:[1037..1045] involved)
        (NP-1 (-NONE-:[1045..1045] *))
        (PP-CLR (IN:[1046..1048] in)
          (NP
            (NP (NN:[1049..1063] downregulation))
            (PP (IN:[1064..1066] of)
              (NP
                (NP (DT:[1067..1070] the) (NN:[1071..1079] activity))
                (PP (IN:[1080..1082] of)
                  (NP (NN:[1083..1086] ras) (HYPH:[1086..1087] -)
                      (NNS:[1087..1095] proteins)))))))))
    (.:[1095..1096] .)))

;sentence 13 Span:1097..1221
;In contrast to  immature neuronal tissues in mature brain, the type II
;isoform of neurofibromin  is predominantly expressed.
;[1160..1192]:gene-protein:"type II isoform of neurofibromin"
(SENT
  (S
    (PP (IN:[1097..1099] In)
      (NP
        (NP (NN:[1100..1108] contrast))
        (PP (TO:[1109..1111] to)
          (NP
            (NP (JJ:[1113..1121] immature) (JJ:[1122..1130] neuronal)
                (NNS:[1131..1138] tissues))
            (PP (IN:[1139..1141] in)
              (NP (JJ:[1142..1148] mature) (NN:[1149..1154] brain)))))))
    (,:[1154..1155] ,)
    (NP-SBJ-1
      (NP
        (NML (DT:[1156..1159] the)
          (NML (NN:[1160..1164] type) (CD:[1165..1167] II))
          (NN:[1168..1175] isoform)))
      (PP (IN:[1176..1178] of)
        (NP (NN:[1179..1192] neurofibromin))))
    (VP (VBZ:[1194..1196] is)
      (ADVP (RB:[1197..1210] predominantly))
      (VP (VBN:[1211..1220] expressed)
        (NP-1 (-NONE-:[1220..1220] *))))
    (.:[1220..1221] .)))

;sentence 14 Span:1222..1319
;Retinoic acid was able to raise the proportion of  type II NF-1 expressed in
;neuroblastoma cells.
;[1273..1285]:gene-protein:"type II NF-1"
;[1299..1312]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (JJ:[1222..1230] Retinoic) (NN:[1231..1235] acid))
    (VP (VBD:[1236..1239] was)
      (ADJP-PRD (JJ:[1240..1244] able)
        (S
          (NP-SBJ (-NONE-:[1244..1244] *))
          (VP (TO:[1245..1247] to)
            (VP (VB:[1248..1253] raise)
              (NP
                (NP (DT:[1254..1257] the) (NN:[1258..1268] proportion))
                (PP (IN:[1269..1271] of)
                  (NP
                    (NP
                      (NML (NN:[1273..1277] type) (CD:[1278..1280] II))
                      (NN:[1281..1285] NF-1))
                    (VP (VBN:[1286..1295] expressed)
                      (NP (-NONE-:[1295..1295] *))
                      (PP-LOC (IN:[1296..1298] in)
                        (NP (NN:[1299..1312] neuroblastoma)
                            (NNS:[1313..1318] cells))))))))))))
    (.:[1318..1319] .)))

;section 15 Span:1323..1368
;PMID: 10877072 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1323..1327] PMID) (::[1327..1328] :) (CD:[1329..1337] 10877072)
        (NN:[1338..1339] -LSB-) (NNP:[1339..1345] PubMed) (::[1346..1347] -)
        (NN:[1348..1355] indexed) (IN:[1356..1359] for)
        (NNP:[1360..1368] MEDLINE-RSB-)))
